Guest Editors
Prof. Julia Fedotova，ITMO University, Russia
Prof. Lucian Hritcu, Universitatea Alexandru Ioan Cuza, Roumania
Prof. Peter Kruzliak, Comenius University, Slovakia
Prof. Vittorio Unfer, nstitut des Etudes Universitaires, Switzerland
Summary
Today's approaches to dissect the neurobiology of depression employ an
unprecedented array of experimental techniques in humans and animals,
including genome-wide DNA sequencing, chromatin immunoprecipitation to
study epigenetic factors, functional brain imaging, optogenetic
electrophysiological tools, viral-mediated gene transfer and an
impressive assortment of genetic mutant mice. The list of molecular
players involved in depression's phenotypes has now expanded to include
genes from diverse aspects of cellular physiology such as numerous
neurotransmitter and neuropeptide systems, steroid hormones,
neurotrophic and cytokine signaling cascades, ion channels, circadian
genes, phytochemicals, and many others. Most of the new targets are
derived from experiments in rodents and, while these studies are
scientifically sound, the targets themselves may or may not be
therapeutically relevant or feasible for human depression.
This special issue in the journal BIOCELL is intended to new molecules
and new approaches for treatment of depression in preclinical and
clinical studies.
Keywords
Neurobiology, Depression, Treatment of Mood Disorders, Novel Molecules, Novel Approaches
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue